J&J Will No Longer Offer Up-Front 340B Discounts to DSH CEs for Stelara and Xarelto; Drugmaker Unilaterally Imposing Rebate Model

Johnson & Johnson Health Care System Inc. (J&J) announced last week that, effective October 15, 2024, disproportionate share hospital (DSH) covered entities will no longer have access to up-front 340B…